8-K: Jushi Holdings Reports Q1 2026 Results: Revenue Up, Margins Expand

Jushi Holdings Inc. announced its first quarter 2026 financial results, reporting a 4% year-over-year revenue increase to $66.4 million and a significant expansion in gross profit margin to 45.0%.

Summary

• Jushi Holdings Inc. reported first quarter 2026 revenue of $66.4 million, a 4% increase compared to the same period last year.
• Gross profit reached $29.9 million, with a gross profit margin of 45.0%, an improvement of 460 basis points year-over-year.
• The company reported a net loss of $19.8 million for the quarter.
• Adjusted EBITDA was $11.4 million, with an Adjusted EBITDA margin of 17.2%.
• Cash, cash equivalents, and restricted cash totaled $42.3 million as of March 31, 2026.
• Net cash provided by operations was $8.6 million.
• Jushi completed a strategic refinancing of its senior secured term loan and second lien secured notes, issuing a new $160.0 million term loan due in 2029.
• The company opened its seventh Beyond Hello dispensary in the Cincinnati, Ohio metropolitan area.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive filing, with strong operational improvements and a strategic refinancing, but tempered by a continued net loss and ongoing market pressures.

Positives

• Revenue increased by 4% year-over-year to $66.4 million.
• Gross profit margin expanded significantly by 460 basis points to 45.0%, driven by improved operational performance.
• Adjusted EBITDA increased to $11.4 million, with a margin of 17.2%.
• Net cash provided by operations improved to $8.6 million.
• The company strengthened its balance sheet through a strategic refinancing, enhancing liquidity and extending debt maturities.
• Jushi-branded product sales increased to 58% of retail revenue, indicating a favorable product mix shift.
• The company opened a new dispensary in Ohio, expanding its retail footprint.
• The potential elimination of Section 280E for medical marijuana operations due to rescheduling to Schedule III is expected to positively impact future tax expenses.

Negatives

• The company reported a net loss of $19.8 million for the first quarter of 2026.
• Despite revenue growth, pricing pressure persists in certain markets.
• Operating expenses increased slightly year-over-year due to expanded operations and higher employee costs.
• Other income (expense) included a $5.0 million loss on debt related to the refinancing.

Risks

• Continued pricing pressure across certain markets.
• Uncertainty regarding the timing and extent of revenue impact from the potential transition to adult-use cannabis sales in Virginia.
• Risks associated with managing growth, including potential future impairment of goodwill or intangibles.
• Reliance on key inputs, suppliers, and skilled labor.
• Potential for product recalls and risks associated with cannabis products manufactured for human consumption.
• U.S. regulatory landscape and enforcement related to cannabis, including political risks.
• Cannabis-related tax risks and challenges from governmental authorities.
• The need to raise additional capital through debt or equity financing.

Future Outlook

The company expects the rescheduling of medical marijuana to Schedule III to positively impact its tax expense on an ongoing basis. The transition to adult use in Virginia is expected to expand the customer base and increase demand, though the timing and extent of revenue impact remain uncertain. Jushi remains focused on operational excellence, optimizing its retail footprint, and making targeted investments.

Management Comments

• "Our first quarter results reflect continued progress in executing our strategy, with year-over-year revenue growth and meaningful margin expansion driven by improvements in operational performance and product quality."
• "Across our grower-processor network, operational efficiencies and increased production volumes are supporting both our retail and wholesale channels, contributing to stronger gross profit and a 460 basis point expansion in gross profit margin year-over-year."
• "Our retail business benefited from contributions from our retail expansion in Ohio and strong performance across our Virginia footprint, while wholesale revenue growth was driven by increased distribution, higher production capacity, and strong demand in key markets such as Massachusetts and Ohio."
• "During the quarter, we strengthened our balance sheet through the successful refinancing of our 2024 Term Loan and Second Lien Notes, enhancing liquidity and extending maturities while preserving balance sheet flexibility."
• "The recent federal rescheduling of state-licensed medical marijuana to Schedule III represents a significant milestone for the industry, eliminating 280E tax constraints for medical operations and supporting a more favorable long-term operating environment."
• "Looking ahead, we remain focused on operational excellence, optimizing our retail footprint, and making targeted, high-return investments across our facilities."

Industry Context

StockSavvy.ai notes that Jushi's Q1 2026 results align with broader trends in the cannabis industry, showing a focus on operational efficiency and margin improvement. The company's strategic refinancing and positive outlook on regulatory changes, particularly the rescheduling of medical marijuana, reflect a proactive approach to navigating the evolving legal and financial landscape of the sector.

Comparison to Industry Standards

• Jushi's gross profit margin of 45.0% in Q1 2026 is a positive indicator, especially when compared to the industry average which can fluctuate significantly based on market maturity and competitive pressures. Many multi-state operators (MSOs) aim for gross margins in the 40-50% range, making Jushi's performance competitive.
• The company's Adjusted EBITDA margin of 17.2% is also a key metric for comparison. While specific industry benchmarks vary, this figure suggests efficient operations relative to revenue, though it may be lower than some highly optimized or mature players in the market.
• The net loss of $19.8 million, while a negative, is not uncommon for cannabis companies investing heavily in expansion and dealing with regulatory complexities and high interest expenses. Companies like Green Thumb Industries (GTII) and Curaleaf (CURA) have also reported net losses in periods of significant investment or market challenges.

Related Party Transactions

• An entity affiliated with Jim Cacioppo, CEO, Chairman, and Founder, and Denis Arsenault, a significant equity holder, participated in the new $160.0 million secured term loan issuance.

Stakeholder Impact

• Shareholders: Potential for long-term value creation through strategic growth and improved financial flexibility, but also continued risk due to net losses and market volatility.
• Creditors: The refinancing of debt strengthens the company's ability to meet its obligations.
• Employees: Expansion of operations and new store openings may lead to increased employment opportunities.
• Suppliers: Increased production volumes and wholesale distribution may lead to greater demand for raw materials and services.

Next Steps

• Seek shareholder approval for the continuance of the parent entity from British Columbia, Canada to Nevada, United States.
• Monitor regulatory developments in Virginia regarding adult-use cannabis legislation.
• Continue to focus on operational excellence and optimizing the retail footprint.
• Make targeted, high-return investments across facilities.
• Monitor the outcome of the federal rescheduling hearing for marijuana.

Key Dates

Recommendation

The company shows positive operational momentum with revenue growth and margin expansion, alongside a crucial debt refinancing. However, the persistent net loss and the inherent risks within the cannabis industry, including regulatory uncertainties, warrant a cautious 'hold' recommendation until profitability is more firmly established and future growth drivers are clearer.

Keywords

Jushi Holdings, cannabis operator, financial results, Q1 2026, revenue growth, gross profit margin, Adjusted EBITDA, refinancing